Merck & Company, Inc. (MRK) Rating Reiterated by BMO Capital Markets

BMO Capital Markets restated their sell rating on shares of Merck & Company, Inc. (NYSE:MRK) in a research report sent to investors on Wednesday, July 5th.

Other research analysts have also recently issued reports about the stock. Vetr cut shares of Merck & from a strong-buy rating to a buy rating and set a $69.99 target price for the company. in a report on Wednesday, May 17th. Zacks Investment Research upgraded shares of Merck & from a hold rating to a buy rating and set a $72.00 target price for the company in a report on Wednesday, May 10th. Credit Suisse Group set a $72.00 target price on shares of Merck & and gave the stock a buy rating in a report on Tuesday, June 6th. BidaskClub upgraded shares of Merck & from a sell rating to a hold rating in a report on Thursday, June 22nd. Finally, Leerink Swann reiterated a market perform rating on shares of Merck & in a report on Monday, March 20th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $69.80.

Merck & (MRK) traded down 0.66% during trading on Wednesday, hitting $63.10. 5,340,999 shares of the stock were exchanged. Merck & has a 12-month low of $57.18 and a 12-month high of $66.80. The stock’s 50-day moving average price is $63.65 and its 200-day moving average price is $63.78. The firm has a market cap of $172.59 billion, a PE ratio of 34.16 and a beta of 0.80.

Merck & (NYSE:MRK) last announced its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 25.75%. The company had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same period last year, the company posted $0.93 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities analysts expect that Merck & will post $3.87 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Merck & Company, Inc. (MRK) Rating Reiterated by BMO Capital Markets” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/08/04/merck-companys-mrk-sell-rating-reiterated-at-bmo-capital-markets-updated-updated-updated.html.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.98%. Merck &’s dividend payout ratio (DPR) is presently 76.11%.

In other Merck & news, Director C Robert Kidder sold 5,000 shares of the stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $63.54, for a total transaction of $317,700.00. Following the transaction, the director now owns 14,317 shares in the company, valued at $909,702.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.05% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Private Advisor Group LLC increased its position in shares of Merck & by 18.7% in the fourth quarter. Private Advisor Group LLC now owns 246,393 shares of the company’s stock valued at $15,075,000 after buying an additional 38,817 shares during the period. Coldstream Capital Management Inc. increased its position in shares of Merck & by 429.3% in the fourth quarter. Coldstream Capital Management Inc. now owns 38,043 shares of the company’s stock valued at $2,240,000 after buying an additional 30,855 shares during the period. JT Stratford LLC bought a new position in shares of Merck & during the fourth quarter valued at approximately $2,394,000. BigSur Wealth Management LLC bought a new position in shares of Merck & during the fourth quarter valued at approximately $981,000. Finally, ARP Americas LLC bought a new position in shares of Merck & during the fourth quarter valued at approximately $235,000. Institutional investors own 73.68% of the company’s stock.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Company Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

19 + ten =